Alnylam Pharmaceuticals
ALNY
#534
Rank
โ‚น3.394 T
Marketcap
โ‚น26,033
Share price
3.98%
Change (1 day)
110.14%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): -โ‚น164.67

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -โ‚น167.53. In 2023 the company made an earnings per share (EPS) of -โ‚น301.73 an increase over its 2022 EPS that were of -โ‚น794.08.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)-โ‚น164.67
2023-โ‚น301.73-62%
2022-โ‚น794.0829.03%
2021-โ‚น615.43-3.36%
2020-โ‚น636.80-8.48%
2019-โ‚น695.787.67%
2018-โ‚น646.2139.74%
2017-โ‚น462.4312.94%
2016-โ‚น409.4338.84%
2015-โ‚น294.90-32.88%
2014-โ‚น439.35259.44%
2013-โ‚น122.23-31.25%
2012-โ‚น177.79

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-โ‚น86.33-48.47%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3,570-2,230.61%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น216.26 29.08%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น4.27-97.45%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น62.40-62.76%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น549.62-428.06%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น243.74-245.49%๐Ÿ‡ซ๐Ÿ‡ท France
-โ‚น97.44-41.84%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel